Export

P-aminosalicylate sodium
Essential medicine status
Section:
6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines
ATC codes: J04AA01
EMLc
Indication
Multi-drug resistant Mycobacterium tuberculosis ICD11 code: ML32.00
Medicine type
Chemical agent
List type
Complementary
Additional notes
Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.
Formulations
Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
EML status history
First added in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
P-aminosalicylate sodium
DrugBank
P-aminosalicylate sodium (Aminosalicylic Acid)
Summary of evidence and Expert Committee recommendations
The Committee recommended deletion from the EML and/or EMLc of various formulations and strengths of amikacin, ethambutol, ethionamide, isoniazid, linezolid, p-aminosalicylic acid and pyrazinamide, noting that they are not optimal formulations and strengths for tuberculosis treatment. A new formulation of p-aminosalicylic acid (as p-aminosalicylate sodium) was recommended for inclusion to replace the previously listed one which has been discontinued by the only manufacturer.